Protective drug dexrazoxane reduces heart damage in pediatric cancer survivors years after treatment ends

A new, high-quality study reveals that the cardioprotective drug dexrazoxane significantly reduces the heart damage caused by chemotherapy received by pediatric cancer patients 15 years or more after treatment ends.

Read more: https://news.ufl.edu/2026/08/chemotherapy-heart-protecting-drug/